Coeptis Therapeutics (NASDAQ:COEP), Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for the treatment of advanced cancers. The company’s research efforts are centered on harnessing both innate and adaptive immune responses to target tumor cells, with a pipeline that includes monoclonal antibodies, cytokine fusion proteins and other biologics designed to overcome immune suppression within the tumor microenvironment.
The company’s lead programs comprise a next-generation PD-1/LAG-3 bispecific antibody designed to enhance T-cell activation, as well as a proprietary STING agonist intended to stimulate innate immune pathways. Coeptis is advancing these candidates through Phase 1/2 clinical studies, both as monotherapies and in combination with existing checkpoint inhibitors, with the aim of improving response rates and durability of remission in solid tumors.
Founded in 2016 following spin-out from a European research consortium, Coeptis has established R&D operations in Waltham, Massachusetts, and maintains strategic partnerships in Germany and China. The company leverages collaborations with leading academic institutions and contract research organizations to accelerate preclinical development, biomarker discovery and clinical trial execution across North America, Europe and Asia-Pacific.
Coeptis is led by Chief Executive Officer Dr. Peter Coleman, who brings over two decades of experience in oncology drug development, alongside Chief Financial Officer Robert J. D’Angelo Jr., a seasoned biotech executive. The management team and board comprise industry veterans with expertise in translational research, regulatory strategy and commercial planning, positioning Coeptis to advance its immuno-oncology portfolio toward regulatory milestones and future market entry.
